Metrics as of 10/13/2026, 06:53 PM (Berlin time), refresh in progress.
Tenax Therapeutics Stock
Tenax Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Christopher T. Giordano
- Employees
- 15
- Market cap
- $42 M
- IPO
- 04/04/1994
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada. Its product pipeline features TNX-103 and TNX-102 (levosimendan), both of which have…
Tenax Therapeutics stock: price history
1D
-12.6%
1W
-17.1%
1M
-14.0%
6M
-89.2%
YTD
-86.9%
1Y
-78.4%
2Y
-52.5%
5Y
-99.9%
10Y
-100.0%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~72% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Tenax Therapeutics
Analyst assessment of Tenax Therapeutics
PRICE TARGET LOW
US$4.00
CONSENSUS
US$4.40
MEDIAN
US$4.00
PRICE TARGET HIGH
US$5.00
0
STRONG BUY
5
BUY
4
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 31/08/2026
Tenax Therapeutics stock metrics
P/E
-1.07
P/B
0.72
EV/EBITDA
1.15
RETURN ON EQUITY
-15.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
99.8%
FLOAT SHARES
26,474,220
AVG. DAILY VOLUME (30D)
3,647,808
Insider transactions (SEC)
Doogan Declan
Giordano Christopher Thomas
Giordano Christopher Thomas
STAAB THOMAS R II
ADAR1 Capital Management, LLC
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Tenax Therapeutics stock
What does Tenax Therapeutics do?
Tenax Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Christopher T. Giordano, the company employs around 15 people.
The IPO was on 04/04/1994; the stock trades on NASDAQ under the ticker TENX.
What do analysts say about Tenax Therapeutics stock?
9 analysts rate the stock, the consensus is Buy (as of 31/08/2026).
The average price target is US$4.40, ranging from US$4.00 to US$5.00, with a median of US$4.00.
This is an external assessment, not a statement by Market Jury.
When does Tenax Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 72% stronger than usual.
Does Tenax Therapeutics pay a dividend?
No, Tenax Therapeutics currently does not pay a dividend.
Which stocks are comparable to Tenax Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Tenax Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Tenax Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.